A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy

Diabetic Medicine

Volumn 13, Issue 12, 1996, Pages 1017-1026

  Nicolucci, A ^a   Carinci, F ^a   Cavaliere, D ^a   Scorpiglione, N ^a   Belfiglio, M ^a   Labbrozzi, D ^a   Mari, E ^a   Massi Benedetti, M ^b   Tognoni, G ^a   Liberati, A ^c  

^a Dept Clin Pharmacol Epidemiol ^*  (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Aldose reductase inhibitors; Diabetic peripheral neuropathy; Meta analysis; Randomized clinical trials; Systematic reviews

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; SORBINIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYALGIA; RASH;

ALDEHYDE REDUCTASE; CONFIDENCE INTERVALS; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; HUMANS; MEDIAN NERVE; MOTOR NEURONS; NEURONS, AFFERENT; PERONEAL NERVE; RANDOMIZED CONTROLLED TRIALS; SURAL NERVE;

EID: 10544220424     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199612)13:12<1017::AID-DIA252>3.0.CO;2-Z     Document Type: Article

References (47)

1. Boulton AJM, Knight J, Drury J. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care 1985; 8: 125-128.
2. Thomas PK, Eliasson SG. Diabetic neuropathy. In: Dyck PJ, Thomas PK and Lambert EH, eds. Peripheral Neuropathy. Philadelphia: Saunders, 1975: 956-981.
3. Jacobs J, Sena M, Fox N. The cost of hospitalization for the late complications of diabetes in the United States. Diabetic Med 1991; 523-529.
4. Bild D, Selby JV, Sinnock P. Lower extremity amputation in people with diabetes. Diabetes Care 1989; 12: 24-31.
5. Most R, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983; 5: 87-91.
6. Greene DA, Lattimer SA, Sima AAF. Are disturbances of sorbitol, phosphoinositide, and Na+ -K+ -ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988; 37: 688-693.
7. Masson EA, Boulton AJM. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence. Drugs 1990; 39: 190-202.
8. Hedges L, Olkin I. Statistical Methods for Meta-analysis. New York: Academic Press, 1985.
9. Greenland S, Quantitative methods in the review of epidemiological literature. Epidemiol Rev 1987; 9: 1-30.
10. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-777.
11. Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polineuropathy - A clinical and neurophysiological study. J Neurol Neurosurg Psychiatry 1981; 44: 991-1001.
12. Young R, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983; 32: 938-942.
13. Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, et al. Aldose reductase inihibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983; 308: 119-125.
14. Lewin IG, O'Brien IAD, Morgan MH, Corrall RJM. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 1984; 26: 445-448.
15. Fagius J, Brattberg A, Jameson S, Berne C. Limited benefit of treatment of diabetic polineuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323-329.
16. Jespersen J, Gram J, Christensen JEJ. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. Haemostasis 1986; 16: 453-457.
17. Christensen JAJ, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double blind study. Acta Neurol Scand 1985; 71: 164-167.
18. Jaspan JB, Herold K, Bartkus C. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Am J Med 1985; 79: 24-37.
19. Lethinen JM, Hyvönen SK, Uusitupa M, Puhakainen E, Halonen T, Kilpeläinen H. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy. J Neurol 1986; 233: 174-177.
20. Martyn CN, Reid W, Young RJ, Ewing DJ, Clarke BF. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Diabetes 1987; 36: 987-990.
21. Guy RJC, Gilbey SG, Sheehy M, Asselman P, Watkins PJ. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 1988; 31: 214-220.
22. O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IAD, Corral RJM. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one-year's treatment with sorbinil. Diabetic Med 1988; 5: 537-542.
23. Sima AAF, Bril V, Nathaniel V, McEwen TAJ, Brown MB, Lattimer SA, Greene DA. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988; 319: 548-555.
24. Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH. Clinical and neurophysiological studies of aldose-reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 1991; 40: 129-133.
25. Boulton AJM, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990; 33: 431-437.
26. Jennings PE, Nightingale S, Le Guen C, Lawson N, Williamson JR, Hoffman P, Barnett AH. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy. Diabetic Med 1990; 7: 63-68.
27. Gill JS, Williams G, Ghatei A, Hetreed AH, Mather HM, Bloom SR. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabete Metab 1990; 16: 296-302.
28. Ziegler D, Mayer P, Rathmann W, Gries FA. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Prac 1991; 14: 63-74.
29. MacLeod AF, Boulton AJM, Owens DR, van Rooy P, van Gerven JMA, MacRury S, et al. A multicentre trial of the aldose reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. Diabete Metab 1992; 18: 14-20.
30. Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med 1992; 9: 463-468.
31. Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, et al. United Kingdom/Scandinavian Ponalrestat Trial. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. J Diab Comp 1992; 6: 123-130.
32. van Gerven JMA, Lemkes HHPJ, van Djk GG. Long-term effects of tolrestat on symptomatic diabetic sensory polineuropathy. J Diab Comp 1992; 6: 45-48.
33. Santiago JV, Sonksen PH, Boulton AJM, MacLeod A, Beg M, Bochenek W, et al. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. J Diab Comp 1993; 7: 170-178.
34. Sorbinil Retinopathy Trial Research Group. The sorbinil retinopathy trial: neuropathy results. Neurology 1993; 43: 1141-1149.
35. Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kito S, Matsuoka K, et al. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabet Med 1993; 10 (suppl 2): 39S-43S.
36. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroder B, Reitman D, Ambroz A. A method assessing the quality of a randomized control trial. Controlled Clin Trials 1981; 2: 31-49.
37. Dvornik D, Millen J, Hicks DR, Kraml M. Tolrestat pharmacokinetics in rat peripheral nerve. J Diab Comp 1994; 8: 18-21.
38. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
39. Boulton AJM, Armstrong WD, Scarpello JHB, Ward JD. The natural history of painful diabetic neuropathy - a 4-year study. Postgrad Med J 1983; 59: 556-559.
40. Ziegler D, Mayer P, Muhlen H, Gries FA. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of Type I (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 822-829.
41. Krentz AJ, Honigsberger L, Nattrass M. Variability of three standard neurophysiological techniques in established symptomatic diabetic polyneuropathy. Diabetes Res 1989; 12: 135-139.
42. Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diab Comp 1993; 7: 157-169.
43. O'Rourke K, Detsky A. Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts. J Clin Epidemiol 1989; 42: 1021-1024.
44. Bhaskar R, Reitman D, Sacks HS, Smith H, Chalmers TC. Loss of patients in clinical trials that measure long-term survival following myocardial infarction. Controlled Clin Trials 1986; 7: 134-148.
45. World Health Organization Europe and European Region of International Diabetes Federation. The St Vincent Declaration. Copenhagen: WHO Europe and European Region of IDF, 1989.
46. Eddy MD, Billings J. The quality of medical evidence: implications for quality of care. Health Affairs, Spring 1988.
47. Young MJ, Breddy MJ, Veves A, Boulton AJM. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. Diabetes Care 1994; 17: 557-560.